Paul Krzyzanowski
Paul is a computational biologist and writer living in Toronto. He's been a contributor to Signals for three years, writing articles for the general public about how biotechnology and biomedical research can be used to solve pressing medical problems. Alongside Paul's experience in computational biology, bioinformatics, and molecular genetics, he's interested in how academic research develops into real world, commercial technology, and what's needed for the Canadian biotech industry needs to grow. Paul is currently a Post-doctoral Fellow at the Ontario Institute of Cancer Research. Prior to joining the OICR, he worked at the Ottawa Hospital Research Institute and earned a Ph.D. from the University of Ottawa, specializing in computational biology. And finally, Paul earned an H.B.Sc. from the University of Toronto a long time ago. Paul's blog can be read at www.checkmatescientist.net
Posts by: Paul
Can stem cells end the need for blood donors?
In a previous post, Chris Kamel recently reviewed the Nature article about direct creation of blood progenitors from skin fibroblasts as discovered by Mick Bhatia’s research group. The fascinating thing about this article is the potential for enabling autologous cell treatments with a reduced risk of iPS-cell-induced cancer. Certainly, no one can deny that creating a […]
Even in pharmaceuticals, it’s an RNA world
In the RNA world hypothesis, RNA based biological life can exist without the need for DNA and proteins to store information, make decisions, and in general, control cells. In 1998, the discovery that small RNAs can play important roles in controlling cells revolutionized biology and perhaps brought us closer to an RNA world. Since then, […]
Personalized medicine is not only a goal, but part of the process, too
The concept of personalized medicine is an intuitive one: knowing what treatment to provide a patient based on their own individual case of a disease. Molecular techniques and various flavours of “-omics” provide high precision in determining the status and types of many diseases, as well as our susceptibility to them. One key application of […]
iPS cells can help speed traditional drug development
Imagine that you’ve just discovered a novel drug that potentially solves a medical problem, one that accelerates wound healing in skin or can reduce the size of cancerous tumors. You can show the effects beautifully in your model tissue culture system and mice obviously respond to the treatment. You decide to call your technology transfer […]
Comments